Levofloxacin concentrations in serum, sputum and lung tissue: Evaluation of its efficacy according to breakpoint

Japanese Journal of Antibiotics

Volumn 52, Issue 11, 1999, Pages 661-666

  Fujita, Atsushi ^a   Miya, Toshimichi ^a   Tanaka, Ryota ^a   Hirayama, Shin ^a   Isaka, Hirotsugu ^a   Ono, Yoko ^a   Koshiishi, Yoshihiko ^a   Goya, Tomoyuki ^a  

^a KYORIN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN;

ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG SPUTUM LEVEL; DRUG TISSUE LEVEL; HUMAN; LUNG PARENCHYMA; ORAL DRUG ADMINISTRATION; PNEUMONIA; RESPIRATORY TRACT INFECTION;

ADULT; AGED; CHRONIC DISEASE; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; OFLOXACIN; PNEUMONIA; RESPIRATORY TRACT INFECTIONS; SALIVA; TIME FACTORS;

EID: 0032793359     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Chemotherapy 40 (Suppl. 3): 57-63, 1992
2. VERHO, M.; V. MALERCZYK & D. DAMM' Pharmacokinetics of levofloxacin in comparing to the racermc mixture of ofloxacin in man. Drg Metabol, Drg. Interact. 13: 57∼67, 1996
3. GOLDSTEIN, E. J.; D. M. CITRON, M. HUDSPETH, S. H. GERARDO & C. V. MERRIAM: In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. Antimicrob. Agents Chemother. 41: 1552∼1557, 1997
4. NAKAMORI, Y.; Y. MIYASHTTA, I. NAKATANI &. K. NAKATA: Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections. Drugs 49: 418∼419, 1995
5. KLIMBERG, I. W.; C. E. Cox, C. L. FOWLER, W. KING, S. S. KIM , D. CALLERY & S. AMICO: A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. Urology 51: 610∼615, 1998
6. WADA, K.; T. KAWASHIMA, H. TSUKADA, N. SUZUKI, Y. SHIMAZL & M. ARAKAWA: Saliva, sputum and serum concentrations of ofloxacin in patients with chronic respiratory tract infections. Chemotherapy 39: 982∼988, 1991
7. WONG F. A.; S. J. JUZWIN & S. C. FLOR: Rapid stereospecific high-performance liquid chromatographic determination of levofloxacin in human plasma and urine. J. Pharm. Biomed. Anal. 15: 765∼771, 1997
8. Chemotherapy 42: 905-914, 1994
9. Chemotherapy 40 (Suppl. 3): 14-26, 1992
10. FUJIMOTO, T. & S. MITSUHASHI: In vitro Antibacterial Activity of DR-3355, the 5-( - )-Isomer of Ofloxacin. Chemotherapy (Basel) 36: 268∼276. 1990
11. TANIGAWARA, Y.; H. NOMURA, N. KAGIMOTO, K. OKAMURA & R. HORI: Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. Biol. Pharm. Bull. 18: 315∼320, 1995